Conversion to a proliferation signal inhibitor in a patient with coronary artery disease - A case report

Nephrology Dialysis Transplantation

Volumn 21, Issue SUPPL. 3, 2006, Pages

  Sparacino, Vito ^a,b   Calabrese, Sergio ^a  

^a Civic Hospital   (Italy)

^b ARNAS Civico   (Italy)

Author keywords

Cardiovascular disease; Ciclosporin; Everolimus; Mammalian target of rapamycin inhibitors; Proliferation signal inhibitors; Sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CYCLOSPORIN A; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PREDNISONE; PROLIFERATION SIGNAL INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART MUSCLE ISCHEMIA; HEART SCINTISCANNING; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIFESTYLE; LIPID BLOOD LEVEL; OBESITY; PRIORITY JOURNAL;

ANGINA PECTORIS; ANGIOPLASTY; AZATHIOPRINE; CALCINEURIN; CELL PROLIFERATION; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SIGNAL TRANSDUCTION; SIROLIMUS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 33745802195     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl303     Document Type: Article

References (19)

1. Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005; 18: 379-384
2. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004; 77: 1199-1202
3. Artz MA, Boots JMM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937-945
4. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748-1756
5. Vítko Š, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635
6. Zhou J, Chew M, Ravn HB, Falk E. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scand J Clin Lab Invest Suppl 1999; 230: 3-11
7. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992; 11 [Suppl]: S38-S44
8. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N Engl J Med 2003; 349: 847-858
9. Eisen H, Starling R, Kobashigawa J. Incidence of MACE and economic burden in de novo heart transplant patients: A 4-year comparison of everolimus and azathioprine. Transplant Int 2005; 18: PO-111
10. Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplant vasculopathy. Circulation 2003; 107: 48-53
11. Segovia J, Alonso-Pulpon L, Ortiz P et al. Rapastat: Evaluation of the role of oral sirolimus in the treatment of established graft vessel disease. A prospective, randomized intravascular ultrasound study. J Heart Lung Transplant 2004; 23 [Suppl 2]: S51
12. Hausleiter J, Kastrati A, Mehilli J et al. Randomized, doubleblind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790-795
13. Morice M-C, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J Med 2002; 346: 1773-1780
14. Costa RA, Lansky AJ, Mintz GS et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95: 113-116
15. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican ®) in renal transplantation: A review of clinical trial data, current usage, and future directions. Transplantation Rev 2006; 20: 1-18
16. Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ. Effects of sirolimus on mesangial cell cholesterol homeostasis: A novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 2005; 289: F43-F48
17. Bellosta S, Arnaboldi L, Canavesi M, Pfister P, Granata A, Dorent R, Corsini A. Everolimus affects cholesterol homeostasis in macrophages. 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. Denver, Co, USA, April 27-29, 2006.
18. Kip1-independent pathway. Atherosclerosis 2004; 172: 31-38
19. Elloso MM, Azrolan N, Sehgal SN et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562-569